Personalized mRNA vaccine cuts melanoma recurrence risk in late-stage trial
⏮ BeforePatients with melanoma at high risk of the cancer returning relied on standard treatment alone.
✅ NowIn a late-stage trial, a personalized mRNA vaccine cut the risk of recurrence and death by 42%.
In short
- Moderna and Merck's personalized mRNA vaccine for melanoma was tested in a late-stage trial.
- The vaccine cut the risk of cancer recurrence and death by 42% compared with standard treatment.
- The result comes from a trial, so wider use depends on further approval.
Why the Good News Desk likes this one
The vaccine is tailored to each patient's tumour, using mRNA technology. In the trial it reduced the risk of cancer returning or death by 42% compared with standard treatment. The finding is from a late-stage trial, so it is a strong signal rather than an approved treatment.
Advertisement
From NBC News
Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
Ask this story
📜 The story so far
- 22 Oct 2026 Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42 Percent Where it started.
- 23 Oct 2026 Moderna mRNA vaccine almost halves risk of melanoma returning The same Moderna melanoma vaccine trial result is now described as almost halving recurrence risk, a rephrasing of the earlier 42 percent figure rather than a new development.
- 23 Oct 2026 Personalized mRNA vaccine cuts melanoma recurrence risk in late-stage trial The same personalized mRNA melanoma vaccine's 42% recurrence-risk reduction is now reported from a late-stage trial, with the risk figure restated as death too.
- 23 Oct 2026 Moderna and Merck personalised melanoma vaccine cuts recurrence in trial The same Moderna and Merck melanoma vaccine trial is reported again, now describing delayed return and spread of the cancer in the trial data.
- 23 Oct 2026 Personalised mRNA cancer vaccine cuts melanoma return risk by 42% The same 42% melanoma result is now reported with more detail, adding that it is a Phase III trial of the Keytruda-combined vaccine.
More like this
Advertisement